Recombinant SSEA-4 anticorps

N° du produit ABIN7477863

Détail du produit anti-SSEA-4 anticorps

Antigène: SSEA-4 (Thiosulfate Sulfurtransferase 4 (SSEA-4))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp SSEA-4 est non-conjugé

Application: ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Western Blotting (WB)

Fonction: Anti-SSEA-4 Antibody (clone E2-F8)

Specificité: Positive Control: Colon cancer tissue

Attributs du produit: SSEA-4 F8 antibody is an unconjugated recombinant rabbit monoclonal antibody to Stage-Specific Embryonic Antigen-4 (SSEA-4). Validated for ELISA, IHC-FR and immunoblotting applications.

Purification: Purified by Protein A or Protein G affinity chromatography

Pureté: >95 %

niveau d'endotoxine: <0.050 EU/mg as determined by Limulus Amebocyte Lysate (LAL) chromogenic endotoxin assay

Clone: E2-F8

Isotype: IgG1

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: PBS buffer ( pH 7.5)

Stock: 4 °C,-20 °C

Stockage commentaire: Store frozen in aliquots at -20°C for up to one year, or at 4°C for up to one week

Date de péremption: 12 months

Détails sur SSEA-4

Antigène: SSEA-4 (Thiosulfate Sulfurtransferase 4 (SSEA-4))

Autre désignation: SSEA4 (SSEA-4 Produits)

Sujet: Stage-specific embryonic antigen-4 (SSEA-4) is a ganglioside which consists of a glycosphingolipid (GSL) containing a terminal sialic acid residue (N-acetylneuraminic acid). SSEA-4 expression changes both qualitatively and quantitatively during development, differentiation and in tumorigenesis. During human development, SSEA-4 is first observed on pluripotent cells of the inner cell mass and is subsequently lost upon differentiation (Tondeur et al. 2008). In addition, human germ stem cells in the testis and ovary express SSEA-4 (Harichandan et al. 2013; Virant-Klun et al. 2013).

SSEA-4 has been found to be over-expressed in a number of cancers and has been correlated with disease progression. Studies by the Buhring group (Sivasubramaniyan et al, 2015) proposed SSEA-4 as a novel marker to identify heterogeneous, invasive subpopulations of tumor cells. Importantly, they also demonstrated that increased cell-surface SSEA-4 expression is associated with the loss of cell–cell interactions and the gain of a migratory phenotype, suggesting an important role of SSEA-4 in cancer invasion by influencing cellular adhesion to the extracellular matrix.

Studies of SSEA-4 expression and function have often been inhibited by the lack of high quality reagents. Due to the glycan nature of the antigen almost all antibodies that have been developed are of IgM or IgG3 classes, which tend to be of low affinity and can be difficult to handle.

Glykogen have overcome these reagent challenges by using their proprietary immunisation methods to develop Clone F8, a recombinant monoclonal rabbit IgG antibody. The availability of this antibody will facilitate studies into SSEA-4 expression and function, both in stem cell biology and in cancer studies.

Poids moléculaire: 143 kD